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Abstract
Background: Patient-reported measures can be used to examine whether drug differences other than
clinical efficacy have an impact on outcomes that may be important to patients. Although exenatide and
insulin glargine appear to have similar efficacy for treatment of type 2 diabetes, there are several
differences between the two treatments that could influence outcomes from the patient's perspective. The
purpose of the current study was to examine whether the two drugs were comparable as assessed by
patient-reported outcomes using data from a clinical trial in which these injectable medications were added
to pre-existing oral treatment regimens.
Methods: Patients were randomized to either twice daily exenatide or once daily insulin glargine during
a 26-week international trial. At baseline and endpoint, five patient-reported outcome measures were
administered: the Vitality Scale of the SF-36, The Diabetes Symptom Checklist – Revised (DSC-R), the
EuroQol EQ-5D, the Treatment Flexibility Scale (TFS), and the Diabetes Treatment Satisfaction
Questionnaire (DTSQ). Change from baseline to endpoint was analyzed within each treatment group.
Group differences were examined with General linear models (GLMs), controlling for country and
baseline scores.
Results: A total of 549 patients with type 2 diabetes were enrolled in the trial, and current analyses were
conducted with data from the 455 per protocol patients (228 exenatide and 227 insulin glargine). The
sample was primarily Caucasian (79.6%), with slightly more men (55.2%) than women, and with a mean age
of 58.5 years. Paired t-tests found that both treatment groups demonstrated statistically significant baseline
to endpoint change on several of the health outcomes instruments including the DSC-R, DTSQ, and the
SF-36 Vitality subscale. GLMs found no statistically significant differences between groups in change on the
health outcomes instruments.
Conclusion: This analysis found that both exenatide and insulin glargine were associated with significant
improvements in patient-reported outcomes when added to oral medications among patients with type 2
diabetes. Despite an additional daily injection and a higher rate of gastrointestinal adverse events,
treatment satisfaction in the exenatide group was comparable to that of the glargine group, possibly
because of weight reduction observed in patients treated with exenatide.
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Background
In clinical trials, patient-reported outcome measures can
complement clinical outcomes by providing information
beyond traditional efficacy and safety measures. When
new treatments have comparable efficacy, patient-
reported instruments can be used to examine whether
drug differences other than clinical efficacy have an
impact on outcomes that may be important to patients
[1]. Two injectable treatments for patients with type 2 dia-
betes, insulin glargine and exenatide, have been found to
have comparable efficacy as measured by HbA1c reduction
in a recent 26-week randomized controlled trial [2]. When
added to oral medications in this trial, both exenatide and
insulin glargine reduced HbA1c levels by 1.1%. Insulin, in
conventional and analog forms, is a commonly used treat-
ment for such patients [3,4]. Insulin glargine is a long-act-
ing analog with absorption kinetics that provides a
relatively consistent basal insulin supplied for approxi-
mately 24 hours [5,6]. Exenatide is a recently approved
medication that elicits several of the glucoregulatory
actions of glucagon-like peptide-1, an incretin hormone
that is an essential regulator of normal glucose homeosta-
sis [2,7-14]. Exenatide has post-parandial and fasting
blood glucose effects [2]. Although exenatide and insulin
glargine appear to have similar efficacy for reduction of
HbA1c, there are several differences between the two treat-
ments that could influence outcomes from the patient's
perspective. Therefore, the purpose of the current study
was to conduct a secondary analysis of clinical trial data to
examine whether the two drugs were comparable as
assessed by patient-reported outcomes.
One difference between these two medications that could
lead to differences in patient-reported outcomes is that
they have different effects on patients' body weight.
Whereas insulin is associated with increased risk of weight
gain [15-17], exenatide has repeatedly been found to be
associated with weight reduction [7,8,11,12,14]. For
example, in a 26-week head-to-head clinical trial, insulin
glargine-treated patients had a mean body weight increase
of 1.8 kg from a baseline mean of 88.3 kg, whereas
exenatide-treated patients decreased in body weight by
2.3 kg from a baseline mean of 87.5 kg [2]. Weight reduc-
tion is likely to lead to positive health outcomes for many
patients as it has been shown to improve glycemic control
and reduce long-term health risks [16,18-21]. Further-
more, lower weight has been found to be associated with
greater patient-reported treatment satisfaction and health-
related quality of life (HRQL) among patients with diabe-
tes [22-24]. HRQL can be defined as the patient's subjec-
tive perception of the impact of health status on physical,
psychological, and social functioning [1,25].
Exenatide and insulin also differ in side effect profiles. In
clinical trials, the most frequent adverse events reported
by patients with exenatide have been gastrointestinal side
effects, such as nausea and to a lesser extent vomiting, that
tend to occur early in treatment [2,7,8,11,12,14]. These
gastrointestinal symptoms are generally found to be mild-
to-moderate, and they have only a negligible contribution
to the weight effects of exenatide [26,27]. Patients treated
with insulin glargine have reported a lower incidence of
these side effects [2]. Another difference between the two
drugs involves dose frequency. Insulin glargine is admin-
istered once per day, whereas exenatide is administered
twice per day. In general, reduced dose frequency is
thought to be associated with greater treatment satisfac-
tion, although there are exceptions for some patients, dis-
eases, and medications [28-32]. To assess the potential
impact of these differences between exenatide and insulin
glargine, the current study analyzed change in five patient-
reported outcome measures, using data from a clinical
trial in which the two drugs had comparable efficacy [2].
These outcome measures assessed HRQL, treatment satis-
faction, vitality, treatment flexibility, and impact of diabe-
tes symptoms.
Methods
Data source
Data from a 26-week, multicenter, comparator-control-
led, open-label, randomized, two-arm, clinical trial were
used for this analysis. Data were collected in 13 countries
(Australia, Belgium, Brazil, Finland, Germany, Norway,
Poland, Portugal, Puerto Rico, Spain, Sweden, the Nether-
lands, and the United States). All patients were required to
have type 2 diabetes that was inadequately controlled
with orally administered sulfonylurea and metformin
(i.e., HbA1c between 7.0% and 10.0%). Patients were ran-
domized to add one of two injectable medications to their
oral treatment regimen: exenatide (taken twice-daily, 15
minutes before morning and evening meals; fixed dose of
5 micrograms bid for the first 4 weeks and subsequently
increased to 10 micrograms bid) or insulin glargine
(forced titration to FBS target ≤ 5.5 mmol/L; administered
once daily at bedtime). The oral medications were main-
tained at pre-study dose levels unless patients experienced
hypoglycemia, in which case a 50% reduction in sulfony-
lurea dose was recommended. The primary objective of
the study was to test the hypothesis that glycemic control,
as measured by change in HbA1c, achieved with exenatide
is non-inferior to that of insulin glargine. The current sec-
ondary analysis was conducted to compare the two treat-
ment groups with respect to change in patient-reported
health outcomes measures. Clinical findings, dropout
rates for each treatment group, reasons for study with-
drawal, and further description of the trial design are pub-
lished elsewhere [2].Health and Quality of Life Outcomes 2006, 4:80 http://www.hqlo.com/content/4/1/80
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Measures
In this trial, patients completed five health outcomes
instruments at baseline (week 0) and endpoint (week 26),
including two generic and three condition-specific meas-
ures. Because generic and condition-specific measures
have different strengths, it is often recommended to
include both types of instruments in clinical trials [33-36].
Compared with generic measures, the primary advantage
of condition-specific measures is that they are frequently
found to be more responsive to treatment-related change
[37]. An advantage of generic PROs is that they can be
used to compare among various populations, make com-
parisons to the general population, and estimate the rela-
tive impact of various medical conditions or treatments
[1,38-40]. In addition, generic measures usually assess
impact of disease and treatment on overall functioning or
a broader range of health domains than condition-specific
measures [34,39].
Diabetes Symptom Checklist – revised (DSC-R)
The DSC-R is a revised version of the DSC-2, which was
developed to measure both the frequency and perceived
discomfort of physical and psychological symptoms asso-
ciated with type 2 diabetes and its potential complications
[41]. On the 34 items of the DSC-R, participants first indi-
cate whether they have experienced each symptom in the
past month by circling "yes" or "no". If "yes" is selected,
the participant proceeds to rate the perceived discomfort
of the symptom on a 5-point scale ranging from 1 (not at
all) to 5 (extremely). When participants report not having
the symptom, the item is scored as zero. The instrument
yields a total score and the following subscales: Fatigue,
Cognitive, Pain, Sensory, Cardiology, Ophthalmology,
Hypoglycemia, and Hyperglycemia. Higher scores indi-
cate greater symptom burden. The total score and all
dimension scores range from 0 to 5, with higher scores
indicating greater discomfort. The DSC-2 has been found
to have good internal consistency reliability, test-retest
reliability, construct validity, and responsiveness [41,42].
No published literature on the psychometric properties of
the DSC-R was located.
Diabetes Treatment Flexibility Scale (TFS)
The TFS is comprised of 10 items from the 142-item Dia-
betes Quality of Life Clinical Trial Questionnaire
(DQLCTQ), which was designed to assess HRQL among
patients with type 1 and type 2 diabetes in multinational
clinical trials [43]. The 10 TFS items evaluate how much
choice patients have in their decisions concerning meals
and physical, social, and other daily activities during the
past four weeks [43]. Five questions focus on meals, while
the other five focus on activities. Each item is answered on
a 5-point Likert scale. The TFS score ranges from 0 to 100,
with higher scores indicating greater flexibility. The instru-
ment has demonstrated good internal consistency relia-
bility and discriminant validity [43,44].
Diabetes Treatment Satisfaction Questionnaire (DTSQ)
The DTSQ was designed to measure satisfaction with dia-
betes treatment regimens among patients with type 1 or
type 2 diabetes [22,45]. The instrument is comprised of
eight items, each rated on a 7-point Likert scale ranging
from 0 to 6. Six of the items contribute to a treatment sat-
isfaction score, and the other two items assess perceived
frequency of hyperglycemia and hypoglycemia. On the
satisfaction scale, which ranges from 0 to 36, higher scores
indicate greater satisfaction. On the hyperglycemia and
hypoglycemia items, higher scores indicate greater prob-
lems. The current study used the "status form" of the
DTSQ (which measures satisfaction at one point in time),
as opposed to the "change form" (which measures change
in satisfaction) [46]. The instrument has been used to
measure outcomes of diabetes management and clinical
trials, and it has been shown to be reliable, and valid, and
sensitive to change [22,29,45,46].
EuroQol EQ-5D
The EQ-5D is a brief questionnaire that is commonly used
to provide an estimate of overall health status in large-
scale surveys, clinical research, and health economic eval-
uation [47]. The EQ-5D descriptive system consists of five
dimensions of health (mobility, self-care, usual activities,
pain/discomfort, and anxiety/depression). Each dimen-
sion is assessed by one item with three response choices:
no problems, some problems, and severe problems. These
five ratings are used to derive the weighted EQ-5D index
score, a single score representing overall health with
higher scores indicating better health status. An index
score of 1 corresponds to perfect health, and 0 corre-
sponds to death, although negative scores representing
health states worse than death are possible [48,49]. Relia-
bility, validity, and responsiveness of the EQ-5D have
been demonstrated in general population samples as well
as samples of patients with a wide range of medical con-
ditions [47]. Mean scores for general samples of patients
with type 2 diabetes in previous studies range from
roughly 0.69 to 0.77 [50-52]. Scores tend to be somewhat
lower among patients with complications, patients being
treated with insulin, patients with obesity, and older
patients.
Vitality scale of the SF-36 (medical outcomes study short 
form-36 item health survey)
The SF-36 was created to collect health status information
across a variety of diseases and treatment groups [53,54].
The instrument was designed to be appropriate for use in
a variety of settings including clinical practice, clinical
research, health policy evaluations, and general popula-
tion surveys. The SF-36 consists of 8 subscales, but onlyHealth and Quality of Life Outcomes 2006, 4:80 http://www.hqlo.com/content/4/1/80
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the 4-item vitality subscale was administered in the cur-
rent trial to assess energy level and fatigue. The four items
are rated on 6-point Likert scales: two items that are
worded positively ("Did you feel full of pep"; "Did you
have a lot of energy") and two items that are worded neg-
atively ("Did you feel worn out"; "Did you feel tired").
Scores range from 0 to 100, with higher scores reflecting
less fatigue and greater energy. Reliability and validity of
SF-36 scales have been evaluated in multiple studies and
have generally been found to be acceptable [54,55]. Mean
subscale scores for patients with type 2 diabetes have typ-
ically ranged from approximately 40 to 60 in previous
studies, and scores have been shown to improve with
treatment [56,57]. Vitality scores have also been shown to
decline with the onset of diabetes complications [58].
Statistical analysis
This analysis was conducted with the per protocol sample,
which included all patients who had at least 12 weeks of
exposure to study medication and no violations of inclu-
sion/exclusion criteria or discontinuation criteria (e.g.,
1.5% increase in HbA1c, more than 10 consecutive days of
study medication are missed, or a female patient becomes
pregnant). For patients who completed the endpoint anal-
ysis earlier than week 26, a last observation carried for-
ward (LOCF) approach was used (i.e., substituting data
gathered at week 12, 18, or 26).
Categorical demographic and clinical variables are pre-
sented in terms of frequency and percents, whereas con-
tinuous variables are summarized in terms of means and
standard deviations. To evaluate within-group change in
each health outcomes measure, paired t-tests were con-
ducted to compare baseline and endpoint scores. To
examine differences between the two treatment groups,
general linear models were performed, controlling for
country and baseline score. The dependent variable in
each model was the health outcome measure change score
(endpoint – baseline). Separate models were conducted
for each instrument's total and subscale scores. Finally,
because exenatide was associated with a higher incidence
of nausea than insulin glargine [2], change in treatment
satisfaction (as measured by the DTSQ) was also assessed
separately among subgroups of exenatide-treated and
insulin glargine-treated patients who experienced nausea
at any time during the trial. Results of all analyses were
considered statistically significant at a level of p < 0.05.
Because these analyses were considered exploratory, no
adjustments for multiple comparisons were made.
Results
A total of 549 patients were enrolled in the trial. The cur-
rent analyses were conducted with data from the 455
patients that were considered per protocol (228 exenatide
and 227 insulin glargine). Demographic and clinical char-
acteristics of the total sample and two treatment groups
are presented in Table 1. The total per protocol sample
was primarily Caucasian (79.6%), with slightly more men
(55.2%) than women. The mean age was 58.5 years, and
patients had type 2 diabetes for a mean of 9.5 years. Mean
HbA1c and BMI at baseline were 8.3% and 31.5 kg/m2,
respectively. There were no statistically significant differ-
ences at baseline between the two treatment groups in
these demographic and clinical variables.
Paired t-tests revealed that both treatment groups demon-
strated statistically significant baseline to endpoint
change on several of the health outcomes instruments
(Table 2). Both the exenatide-treated group and the insu-
lin glargine-treated group demonstrated statistically sig-
nificant improvement in the DSC-R total score (p <
0.0001 for exenatide and p = 0.0002 insulin glargine), the
Table 1: Demographic and clinical characteristics
Characteristic Exenatide (N = 228) Insulin Glargine
(N = 227)
Total (N = 455) p value1
Age (mean, SD) 59.4 (8.9) 57.7 (9.4) 58.5 (9.2) 0.06
Gender (N, % male) 125 (54.8%) 126 (55.5%) 251 (55.2%) 0.92
Ethnicity (N, %)
Caucasian 181 (79.4%) 181 (79.7%) 362 (79.6%) 0.69
Hispanic 37 (16.2%) 35 (15.4%) 72 (15.8%)
Western Asian 5 (2.2%) 2 (0.9%) 7 (1.5%)
African Descent 1 (0.4%) 3 (1.3%) 4 (0.9%)
Native American 0 (0.0%) 1 (0.4%) 1 (0.2%)
Other 4 (1.8%) 5 (2.2%) 9 (2.0%)
Duration of Diabetes in years (mean, SD) 9.7 (5.6) 9.2 (5.9) 9.5 (5.7) 0.21
HBA1c (mean, SD) 8.3% (0.9%) 8.3% (1.0%) 8.3% (1.0%) 0.55
BMI (mean kg/m2, SD) 31.6 (4.5) 31.4 (4.5) 31.5 (4.5) 0.53
1 P values are for comparisons between the 2 treatment groups. T-tests were used for continuous variables, and Fisher's exact tests were used for 
categorical variables.Health and Quality of Life Outcomes 2006, 4:80 http://www.hqlo.com/content/4/1/80
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DTSQ satisfaction score (p < 0.0001 for both treatment
groups), and the SF-36 Vitality subscale (p = 0.005 for
exenatide and p < 0.04 for insulin glargine). Both groups
also had statistically significant differences between base-
line and endpoint scores on several of the DSC-R sub-
scales (psychology: fatigue, psychology: cognitive,
ophthalmology, hypoglycemia, hyperglycemia) as well as
the hyperglycemia and hypoglycemia items of the DTSQ.
In addition, the insulin glargine group demonstrated sig-
nificant baseline to endpoint change on the EQ-5D index
score and the DSC-R cardiology score.
Results of general linear models comparing change in
health outcomes between the two treatment groups, con-
trolling for country and baseline score, are presented in
Table 3. Results of these models indicate that there were
no statistically significant differences between groups in
the health outcomes instruments.
Finally, because exenatide has been found to be associated
with a higher incidence of nausea than insulin glargine,
treatment satisfaction was examined separately among
subgroups of patients who experienced nausea at any time
during the trial. In the exenatide group, 126 patients
reported experiencing nausea at any time during the trial,
compared with 22 insulin glargine-treated patients. The
subgroup of 126 exenatide-treated patients had mean
DTSQ satisfaction scores of 26.9 (SD = 6.8) at baseline
and 29.0 (SD = 6.2) at endpoint. A paired t-test found that
this improvement (change score = 2.1; SD = 7.4) was sta-
tistically significant (t = 3.1, p = 0.002). Findings for the
22 insulin glargine-treated patients were similar. The base-
line mean DTSQ satisfaction score was 24.1 (SD = 6.3),
and the endpoint score was 30.4 (SD = 4.8). This improve-
ment was also statistically significant (change score = 6.2;
SD = 6.3; t = 4.6, p = 0.0001).
Discussion
The current findings add to previous literature suggesting
that, among patients whose glucose levels and symptoms
are not adequately controlled by oral medications, the
improved efficacy offered by the addition of injectable
medication may lead to improved treatment satisfaction
and quality of life [57,59,60]. This analysis found that
both exenatide and insulin glargine were associated with
significant improvements in patient-reported outcomes
when added to oral medications among patients with type
2 diabetes. Patients in both treatment groups demon-
strated statistically significant baseline-to-endpoint
improvement in overall treatment satisfaction as meas-
ured by the DTSQ and vitality as measured by a subscale
of the SF-36. Both groups also had significant reductions
in overall symptom impact and problems with several
specific symptom domains as measured by the DSC-R
(e.g., fatigue, cognition, ophthalmology, hypoglycemia,
hyperglycemia). Insulin glargine-treated patients also had
statistically significant improvement in overall HRQL as
assessed by the EQ-5D. Some studies have reported that
patients with type 2 diabetes on oral medications have
greater HRQL than patients on insulin [24,51,61-63].
However, current findings are consistent with other stud-
ies showing increased HRQL and patient satisfaction after
initiating insulin therapy [57,59,60]. Findings were con-
sistent for both drugs despite different side effect profiles
and the fact that exenatide was administered twice daily
while insulin glargine was administered once daily.
Analyses comparing patient-reported outcomes of the two
drugs found no significant differences between treatment
groups despite drug differences in several areas such as
weight change, side effect profile, and dose frequency.
Although exenatide is associated with increased injections
and gastrointestinal side effects compared with insulin
Table 2: Paired t-tests comparing baseline and endpoint scores within each treatment group
Health Outcomes Measure (mean, SD) Exenatide Insulin Glargine
Baseline Endpoint p value Baseline Endpoint p value
DSC-R Overall Score 1.07 (0.83) 0.90 (0.80) < 0.0001 0.99 (0.78) 0.84 (0.73) 0.0002
EQ-5D Index Score 0.82 (0.22) 0.85 (0.19) 0.08 0.84 (0.22) 0.87 (0.20) 0.049
Diabetes Treatment Flexibility Score 60.37 (22.24) 60.48 (22.33) 0.93 58.85 (22.81) 58.95 (23.37) 0.93
Diabetes Treatment Satisfaction Score 26.41 (7.00) 29.48 (6.12) < 0.0001 26.31 (6.33) 30.04 (5.21) < 0.0001
SF-36 Vitality Subscale Score 53.18 (20.87) 56.30 (20.58) 0.005 55.18 (21.35) 57.62 (20.37) 0.04
DSC-R Psychology: Fatigue Score 1.83 (1.26) 1.49 (1.21) < 0.0001 1.60 (1.29) 1.34 (1.17) 0.0003
DSC-R Psychology: Cognitive Score 1.18 (1.12) 0.99 (1.08) 0.0006 1.14 (1.09) 0.91 (0.99) 0.0001
DSC-R Neurology: Pain Score 0.76 (0.98) 0.70 (0.99) 0.21 0.67 (0.90) 0.63 (0.92) 0.49
DSC-R Neurology: Sensory Score 0.91 (1.07) 0.83 (1.01) 0.10 0.77 (0.94) 0.78 (0.93) 0.83
DSC-R Cardiology Score 0.78 (0.89) 0.71 (0.86) 0.16 0.73 (0.86) 0.61 (0.80) 0.02
DSC-R Ophthalmology Score 0.79 (1.00) 0.62 (0.86) 0.003 0.79 (0.98) 0.64 (0.92) 0.006
DSC-R Hypoglycemia Score 1.09 (1.16) 0.94 (1.09) 0.03 1.10 (1.09) 0.93 (1.00) 0.009
DSC-R Hyperglycemia Score 1.47 (1.31) 1.07 (1.15) < 0.0001 1.42 (1.25) 1.02 (1.13) < 0.0001
DTSQ Frequency High Blood Sugar 3.61 (1.76) 2.19 (1.61) < 0.0001 3.57 (1.67) 2.11 (1.45) < 0.0001
DTSQ Frequency Low Blood Sugar 1.02 (1.37) 1.36 (1.56) 0.007 0.80 (1.21) 1.50 (1.43) < 0.0001Health and Quality of Life Outcomes 2006, 4:80 http://www.hqlo.com/content/4/1/80
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glargine, these potential problems did not appear to result
in less patient satisfaction among the exenatide-treated
patients. It is possible that, for patients who experienced
gastrointestinal side effects from exenatide, the weight
reduction benefits associated with the drug outweighed its
disadvantages, thus resulting in the observed gains in
treatment satisfaction. In addition, although increased
dosing frequency often leads to reduced patient satisfac-
tion, this finding is not consistent across all diseases and
medications [32]. For example, one previous study con-
ducted with patients who had type 2 diabetes found no
treatment satisfaction differences between patients receiv-
ing once-daily injections and those receiving twice-daily
injections [28]. Both current results and these previous
findings suggest that dosing frequency may not be of pri-
mary importance to patients receiving injectable medica-
tion for type 2 diabetes.
Several aspects of the current study design may have lim-
ited the ability to detect true differences in patient experi-
ence with these two medications. First, is possible that a
naturalistic study conducted with less structure than a
clinical trial might yield different findings. For example, if
patients have less contact with medical professionals, they
might be less adherent to a more complicated dosing reg-
imen. A second possible limitation is the relatively brief
study duration. In longer trials of these medications,
patients have experienced greater weight change than in
this 26-week trial [64], and greater weight change is likely
to have a stronger impact on treatment satisfaction and
vitality. Third, a larger sample size would provide greater
statistical power for detecting statistically significant dif-
ferences between treatment groups, if in fact there are true
differences. Finally, the only HRQL instrument adminis-
tered in this trial was the brief EQ-5D, which may not be
sufficiently sensitive to between-treatment group HRQL
differences in this population. Perhaps a multidimen-
sional generic HRQL measure or a condition-specific
HRQL measure would have been able to detect differ-
ences.
Another factor limiting the interpretation of data is that
minimally important differences (MIDs) have not been
identified for the three condition-specific instruments
used in this study (i.e., DSC-R, DTSQ, and TFS). MID is
defined as the smallest change score that a patient would
perceive as beneficial [65,66]. For patient-reported out-
come measures, the minimally important difference
(MID) is used as a guideline to interpret whether improve-
ment can be considered clinically significant or meaning-
ful to patients. Although both treatment groups
demonstrated statistically significant change in most of
the condition-specific scales, it is not known whether
these changes are clinically meaningful.
Previous research has identified MIDs of the two generic
instruments used in the current study. MIDs have been
suggested to be roughly 3 to 5 for the SF-36 and 0.07 for
the EQ-5D, although these MIDs were not derived within
samples of patients with diabetes [67,68]. Neither treat-
ment group in the current study met the MID criterion for
the EQ-5D. On the SF-36 vitality subscale, the exenatide-
treated group changed by 3.12 points, which does exceed
the lower estimate of MID for this scale, while the insulin
glargine group improved by 2.44 points. However, inter-
pretation of treatment effects should not be made based
solely on these generic measures because generic instru-
ments tend to be less responsive to change than condi-
Table 3: Change in health outcomes associated with exenatide and insulin glargine
Health Outcomes Measure Exenatide Insulin Glargine
N LS Mean SE N LS Mean SE p value1
DSC-R Overall Score 223 -0.16 0.04 219 -0.16 0.05 0.96
EQ-5D Index Score 217 0.02 0.01 215 0.03 0.01 0.35
Diabetes Treatment Flexibility Score 222 0.32 1.28 219 -0.46 1.27 0.59
Diabetes Treatment Satisfaction Score 213 3.42 0.43 213 3.85 0.43 0.38
SF-36 Vitality Subscale Score 223 2.41 1.24 220 2.81 1.25 0.78
DSC-R Psychology: Fatigue Score 222 -0.28 0.08 220 -0.31 0.08 0.73
DSC-R Psychology: Cognitive Score 223 -0.24 0.06 220 -0.29 0.06 0.52
DSC-R Neurology: Pain Score 222 -0.04 0.06 219 -0.03 0.06 0.93
DSC-R Neurology: Sensory Score 223 -0.03 0.06 219 0.02 0.06 0.45
DSC-R Cardiology Score 223 -0.08 0.06 219 -0.14 0.06 0.30
DSC-R Ophthalmology Score 222 -0.19 0.06 219 -0.16 0.06 0.68
DSC-R Hypoglycemia Score 221 -0.20 0.07 219 -0.22 0.07 0.81
DSC-R Hyperglycemia Score 223 -0.35 0.07 220 -0.39 0.07 0.58
DTSQ Frequency High Blood Sugar 219 -1.40 0.12 218 -1.48 0.12 0.58
DTSQ Frequency Low Blood Sugar 218 0.37 0.12 216 0.58 0.12 0.13
1Comparisons between treatment groups were performed with general linear models. One model was conducted with each health outcomes 
measure as the dependent variable, controlling for country and baseline score.Health and Quality of Life Outcomes 2006, 4:80 http://www.hqlo.com/content/4/1/80
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tion-specific instruments [37]. Therefore, future research
on MIDs in the three diabetes-specific measures is neces-
sary in order to estimate the clinical significance of
patient-reported improvement in the current study.
Treatment satisfaction is important largely because it is
thought to provide an indication of treatment adherence
[69-71]. In general, patients who are satisfied with their
treatment can be expected to adhere to prescribed treat-
ment regimens more than patients who are unsatisfied.
Therefore, patient satisfaction is necessary in order to
maximize treatment effectiveness. In sum, current results
indicate that both exenatide and insulin glargine were
associated with increased treatment satisfaction and vital-
ity as well as decreased symptom burden.
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